uploads/2018/03/Humalog.png

Eli Lilly’s Endocrinology Drugs Humalog, Humatrope, and Humulin

By

Updated

Humalog’s revenue trends

In 4Q17, Eli Lilly’s (LLY) Humalog reported revenues of $782.2 million, which reflected a ~5% YoY (year-over-year) decline and a ~12% quarter-over-quarter growth.

In 4Q17, in the US market and international markets, Humalog reported revenues of $463.4 million and $318.8 million, respectively, compared to $524.8 million and $295 million, respectively, in 4Q16.

In fiscal 2017, Humalog reported revenues of $2.9 billion, which reflected a ~3% growth YoY.

In 2017, in the US market and international markets, Humalog generated revenues of $1.7 billion and $1.1 billion, respectively, compared to $1.7 billion and $1.1 billion, respectively, in 2016.

Article continues below advertisement

Humatrope’s revenue trends

In 4Q17, Humatrope reported revenues of $103.2 million, which is a ~10% YoY growth and a ~27% quarter-over-quarter growth.

In 4Q17, in the US market and international markets, Humatrope reported revenues of $59.3 million and $43.9 million, respectively, compared to $50 million and $43.5 million, respectively, in 4Q16.

In fiscal 2017, Humatrope reported revenues of $329.9 million compared to $304.5 million in 2016. In 2017, in the US market and international markets, Humatrope generated revenues of $163.2 million and $166.7 million, respectively, compared to $132.9 million and $171.5 million, respectively, in 2016.

In the insulin marketplace, Humatrope’s peers include Novo Nordisk’s (NVO) Norditropin and Pfizer’s (PFE) Genotropin.

Humulin’s revenue trends

In 4Q17, Humulin reported revenues of $362.6 million, which reflected a ~2% growth on a YoY basis and a ~21% growth quarter-over-quarter.

In 4Q17, in the US market and international markets, Humulin reported revenues of $249.7 million and $112.8 million, respectively, compared to $221.8 million and $133.5 million, respectively, in 4Q16.

In fiscal 2017, Humulin reported revenues of $1.3 billion compared to $1.4 billion in 2016. In 2017, in the US market and international markets, Humulin generated revenues of $884.6 million and $450.7 million, respectively, compared to $861.8 million and $504.1 million, respectively, in 2016.

In the insulin injections market, Humilin’s peers include Novo Nordisk’s (NVO) Levemir and Sanofi’s (SNY) Lantus.

Advertisement

More From Market Realist